OBJECTIVES: Assessment of early outcomes in patients with normal preoperative left ventricular ejection fraction (LVEF) in whom venoarterial extracorporeal membrane oxygenation (VA-ECMO) was implanted for postcardiotomy cardiogenic shock (PCCS) during the first postoperative 48 h. METHODS: Retrospective single-centre analysis in adult patients with normal LVEF, who received VA-ECMO support for PCCS from May 1998 to May 2018. The primary outcome was 30-day perioperative mortality during the index hospitalization. RESULTS: A total of 62 125 adult patients underwent cardiac surgery at our institution during the study period. Among them, 173 patients (0.3%) with normal preoperative LVEF required VA-ECMO for PCCS. Among them, 71 (41.1%) patients presented PCCS due to coronary malperfusion and in 102 (58.9%) patients, no evident cause was found for PCCS. Median duration of VA-ECMO support was 5 days (interquartile range 2-8 days). A total of 135 (78.0%) patients presented VA-ECMO-related complications and the overall 30-day perioperative mortality was 57.8%. Independent predictors of mortality were: lactate level just before VA-ECMO implantation [odds ratio (OR) 1.27; P < 0.001], major bleeding during VA-ECMO (OR 3.76; P = 0.001), prolonged cardiopulmonary bypass time (OR 1.01; P < 0.001) and female gender (OR 4.87; P < 0.001). CONCLUSIONS: Mortality rates of VA-ECMO in PCCS patients are high, even in those with preoperative normal LVEF. Coronary problems are an important cause of PCCS; however, the aetiology remains unknown in the vast majority of the cases. The implantation of VA-ECMO before development of tissue hypoperfusion and the control of VA-ECMO-associated complications are the most important prognostic factors in PCCS patients. Lactate levels may help guide timing of VA-ECMO implantation and define the extent of therapeutic effort.
OBJECTIVES: Assessment of early outcomes in patients with normal preoperative left ventricular ejection fraction (LVEF) in whom venoarterial extracorporeal membrane oxygenation (VA-ECMO) was implanted for postcardiotomy cardiogenic shock (PCCS) during the first postoperative 48 h. METHODS: Retrospective single-centre analysis in adult patients with normal LVEF, who received VA-ECMO support for PCCS from May 1998 to May 2018. The primary outcome was 30-day perioperative mortality during the index hospitalization. RESULTS: A total of 62 125 adult patients underwent cardiac surgery at our institution during the study period. Among them, 173 patients (0.3%) with normal preoperative LVEF required VA-ECMO for PCCS. Among them, 71 (41.1%) patients presented PCCS due to coronary malperfusion and in 102 (58.9%) patients, no evident cause was found for PCCS. Median duration of VA-ECMO support was 5 days (interquartile range 2-8 days). A total of 135 (78.0%) patients presented VA-ECMO-related complications and the overall 30-day perioperative mortality was 57.8%. Independent predictors of mortality were: lactate level just before VA-ECMO implantation [odds ratio (OR) 1.27; P < 0.001], major bleeding during VA-ECMO (OR 3.76; P = 0.001), prolonged cardiopulmonary bypass time (OR 1.01; P < 0.001) and female gender (OR 4.87; P < 0.001). CONCLUSIONS: Mortality rates of VA-ECMO in PCCS patients are high, even in those with preoperative normal LVEF. Coronary problems are an important cause of PCCS; however, the aetiology remains unknown in the vast majority of the cases. The implantation of VA-ECMO before development of tissue hypoperfusion and the control of VA-ECMO-associated complications are the most important prognostic factors in PCCS patients. Lactate levels may help guide timing of VA-ECMO implantation and define the extent of therapeutic effort.
Authors: Adrian F Hernandez; Joshua D Grab; James S Gammie; Sean M O'Brien; Bradley G Hammill; Joseph G Rogers; Margarita T Camacho; Mercedes K Dullum; T Bruce Ferguson; Eric D Peterson Journal: Circulation Date: 2007-07-23 Impact factor: 29.690
Authors: Hesham A Elsharkawy; Liang Li; Wael Ali Sakr Esa; Daniel I Sessler; C Allen Bashour Journal: J Cardiothorac Vasc Anesth Date: 2010-12 Impact factor: 2.628
Authors: Nicolas Doll; Bob Kiaii; Michael Borger; Jan Bucerius; Klaus Krämer; Dierk V Schmitt; Thomas Walther; Friedrich W Mohr Journal: Ann Thorac Surg Date: 2004-01 Impact factor: 4.330
Authors: Raymond T C Hu; Jeremy D Broad; Eduardo A Osawa; Paolo Ancona; Yoko Iguchi; Lachlan F Miles; Rinaldo Bellomo Journal: Heart Lung Circ Date: 2020-02-17 Impact factor: 2.975
Authors: Fausto Biancari; Andrea Perrotti; Magnus Dalén; Mariapia Guerrieri; Antonio Fiore; Daniel Reichart; Angelo M Dell'Aquila; Giuseppe Gatti; Tero Ala-Kokko; Eeva-Maija Kinnunen; Tuomas Tauriainen; Sidney Chocron; Juhani K E Airaksinen; Vito G Ruggieri; Debora Brascia Journal: J Cardiothorac Vasc Anesth Date: 2017-09-01 Impact factor: 2.628
Authors: Robert Musiał; Paweł Moncznik; Paweł Śmiałek; Jarosław Stoliński; Jerzy Sadowski; Rafał Drwiła Journal: Kardiol Pol Date: 2016-05-25 Impact factor: 3.108
Authors: Giovanni Mariscalco; Antonio Salsano; Antonio Fiore; Magnus Dalén; Vito G Ruggieri; Diyar Saeed; Kristján Jónsson; Giuseppe Gatti; Svante Zipfel; Angelo M Dell'Aquila; Andrea Perrotti; Antonio Loforte; Ugolino Livi; Marek Pol; Cristiano Spadaccio; Matteo Pettinari; Sigurdur Ragnarsson; Khalid Alkhamees; Zein El-Dean; Karl Bounader; Fausto Biancari Journal: J Thorac Cardiovasc Surg Date: 2019-10-31 Impact factor: 5.209